Neuromeka
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Neuromeka makes collaborative robots, robotic arms designed to work safely alongside people on factory floors, along with the control software and precision drive components that power them.
Its products serve industrial automation needs across sectors such as welding, food processing, manufacturing, and medical applications. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company develops its core components, robot platforms, domain solutions, and AI software entirely in-house, including full in-house development of the actuators that drive robot movement.
Summary is AI-generated and may contain errors · figures from DART filings
The company states it has fully internalized actuator development, the precision drive components at the heart of collaborative robots, autonomous mobile robots, and humanoid robots, rather than sourcing them externally.
Neuromeka in five facts
What does Neuromeka do?
Neuromeka makes collaborative robots, robotic arms designed to work safely alongside people on factory floors, along with the control software and precision drive components that power them.
Where is Neuromeka listed and in which sector?
Neuromeka (Korean name: 뉴로메카) trades under KRX code 348340 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Machinery.
How large is Neuromeka?
Its market capitalisation was US$315.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Neuromeka's latest annual revenue and operating profit?
For fiscal year 2025, Neuromeka reported revenue of US$14.3M, an operating loss of US$11.2M and a net loss of US$16.6M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was down 25.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Supply contract signed
Neuromeka disclosed a supply contract with Dae-Il, worth US$1.46M, about 10.45% of its recent annual revenue, running through Dec 2026.
Supply contract · Oct 1 - Report on securities held by executives/major shareholdersSep 14
- Report on large shareholdings (5% rule) (abbreviated)Sep 1
- Ex-rights (bonus issue)
Neuromeka Co., Ltd. common shares (code A348340) will go ex-rights on August 5, 2026 at a base price of US$14.70, following a bonus share issue.
Capital raise · Aug 4 - Subscription results of rights offering or equity-linked bonds (voluntary)
Neuromeka's rights offering for 3,196,465 common shares saw a subscription rate of 84.62% (2,704,839 shares cumulative), with 491,626 forfeited shares to be fully underwritten by lead manager Korea Investment & Securities and underwriters NH Investment & Securities and Samsung Securities; new shares are scheduled to list on 2026-08-20.
Capital raise · Aug 3 - Subscription results of rights offering or equity-linked bonds (voluntary)
Neuromeka's shareholder-allocated rights offering drew subscriptions for 2,423,049 of the 3,196,465 planned shares (a 75.80% subscription rate) as of 2026-07-28; the resulting 773,416 forfeited shares will be offered in a general public offering on 2026-07-30 to 2026-07-31, with listing expected on 2026-08-20.
Capital raise · Jul 29 - Rights offering: final issue price set
Neuromeka finalized the issue price for its rights offering at US$16.59 per share (versus a first-stage price of US$26.02) for 3,196,465 registered common shares, confirmed on 2026-07-22.
Capital raise · Jul 23 - [Amended] Material event report (paid-in and bonus issue)
Neuromeka updated the terms of convertible bonds to raise US$83.2M, about 23.4% of its market value.
Capital raise · Jul 23 · 4 versions - [Amended] Supply contract signed
Neuromeka updated a previously disclosed supply contract with POSCO, now worth US$1.9M, about 11.61% of its recent annual revenue, running through Mar 2027.
Supply contract · Jul 2 - Ex-rights (rights offering)Capital raise · Jun 18
- Rights offering: round 1 issue price setCapital raise · Jun 18
- Trading suspension (bonus issue)Capital raise · Apr 24
- [Amended] Supply contract signed
Neuromeka updated a previously disclosed supply contract with POSCO, now worth US$1.96M, about 11.61% of its recent annual revenue, running through Dec 2026.
Supply contract · Mar 26 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Neuromeka reported consolidated results for FY2025: revenue of US$12.8M (−25% year on year), an operating loss of US$10.1M and a net loss of US$14.9M.
Earnings · Mar 12 - Material event report (decision to sell own convertible bonds)Capital raise · Jan 26
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jan 6